Understanding breast cancer stem cell heterogeneity: time to move on to a new research paradigm
© Mannello; licensee BioMed Central Ltd. 2013
Received: 27 June 2013
Accepted: 28 June 2013
Published: 23 July 2013
Human breast cancer (BC) is one of the leading causes of death for women worldwide, and is characterized by a group of highly heterogeneous lesions. The morphological and biomolecular heterogeneity of BC cells, accompanied by dynamic plasticity of the BC microenvironment and the presence of stem-like cells, make tumor categorization an urgent and demanding task.
The major limitations in BC research include the high flexibility rate of breast cancer stem cells (BCSCs) and the difficulty of their identification. Improved profiling methods and extensive characterization of BCSCs were recently presented in BMC Cancer, highlighting that the majority of BC cells had a luminal EpCAMhigh/CD49f+ phenotype, and identification of CD44high/CD24low subpopulation of cancer stem cells significantly improves the flow cytometry measurement of BCSCs with higher stem/progenitor ability.
Future developments in single-cell omics will potentially revolutionize cancer biology and clinical practice, providing better understanding of BC heterogeneity, how BCSCs evolve, and which BC cells to target to avoid drug resistance.
Please see related research published in BMC Cancer: http://www.biomedcentral.com/1471-2407/13/289/abstract
KeywordsBiomarkers Breast cancer Cancer heterogeneity CD44/CD24/CD49f Ep-CAM Mammosphere Stem cells
Human breast cancer (BC) represents a group of highly heterogeneous lesions consisting of morphologically distinct subtypes , with different molecular/biochemical signatures , both between and within tumors . BC is one of the leading causes of death for women worldwide, and also has the second highest morbidity rate worldwide . Although the increased rates of diagnosis of early stage disease in recent years has led to a significantly decreased trend in mortality rate, invasive and hormone-independent BC carries still a bad prognosis and still fairly limited therapeutic options, thus there is an urgent need to improve our understanding the biomolecular basis of BC.
The very high rate of heterogeneity in BC cell phenotypes , accompanied by the dynamic plasticity of the breast cancer microenvironment [6, 7], make tumor categorization a demanding task, especially in relation to therapeutic responses and risk of disease progression . The only established reason behind this is the underlying presence of a small population of stem-like cells called breast cancer stem cells (BCSCs) , which are endowed with the capacity for self-renewal and multi-lineage differentiation, tumorigenicity, and chemotherapy and radiotherapy resistance, features that are responsible for tumor progression, disease recurrence, and metastasis .
During the past decades, there have been considerable improvements in isolating and enriching BCSCs, uncovering cellular/tissue biomolecular alterations (through mutation screening, gene expression, microRNA, and proteomic-metabolomic-degradomic profiling). Although the relevant biological role of the breast microenvironment and the cross-talk between epithelial, stromal, and stem cells has been widely and continuously analyzed, the heterogeneity in BC is still not completely understood, which represents a major obstacle to effective cancer treatment and personalized medicine [3, 8].
Breast cancer and stem cell heterogeneity
The clonal expansion and adaptation of BC cells to changing microenvironments , and the acquisition of genetic and epigenetic alterations by these cells  are well-known dynamic processes contributing to the generation of intra-tumor heterogeneity . In particular, BC heterogeneity can arise from the differentiation of stem-like cells along with the clonal selection that occurs during BC progression, and such heterogeneity represents a major challenge for the design of effective therapies. To make inferences about BC progression, it is important to understand the stem cell origins of the inter-tumor and intra-tumor heterogeneity, which requires more effective BCSC biomarkers.
Two main initial theories have provided some mechanism(s) accounting for BC heterogeneity: 1) the theory of cancer stem cells (CSCs), which suggests that different tumors result from different stem cells, and that all cells within a given tumor are capable of progressing to a higher degree of malignancy ; and 2) the theory of clonal evolution, which hypothesizes that different tumors originate from evolution of a single stem cell, and that only the most aggressive clone progresses . A recent study showed that cancer progenitor cells have the capacity to dedifferentiate and acquire a stem cell-like phenotype, indicating that CSC and relatively differentiated progenitors coexist in dynamic equilibrium and are subject to bidirectional conversion .
The dominant role of the tumor microenvironment in determining the CSC phenotype characteristics within a malignancy is noteworthy, as it suggests that tumors contain large populations of tumorigenic and non-tumorigenic tumor cells, whose distribution may vary over time [6, 16]. Like normal stem cells, CSCs also display biologically significant phenotypic and functional heterogeneity, and their progeny can show diverse plasticity , All these tumor cells need to be therapeutically targeted to improve the cure rate in patients with cancer .
Recently, outstanding challenges in identifying CSCs, their dependency on a supportive niche, and their role in metastasis have been addressed by a fluid model , in which the quality of stemness, rather than being fixed entity, is a flexible quality of tumor cells that can be lost and gained .
The major problems/limitations in BC research are represented by the high flexibility of the CSC system (dictated by the microenvironment) and the difficulty of CSC identification (imposed by the current imperfect biomarkers). Although an extensive compilation of molecular CSC markers for distinct human solid tumor types has been reviewed , actually none of the known markers are specific for CSC, and only new cell surface marker combinations may improve and hamper reliability, identification, and enrichment of CSCs, thus new biomarker panels are then urgently needed to recognize and quantify more efficiently both circulating and resident BC CSCs.
It has been previously shown that human BCSCs can be isolated and analyzed based on CD44high, CD24low and high aldehyde dehydrogenase (ALDH) activity [19, 20]. Improved profiling and extensive characterization of BCSCs was presented in BMC Cancer by Ghebeh et al., showing the importance of a new biomarker combination for understanding BC carcinogenesis and heterogeneity .
A new and useful BC stem/progenitor marker combination on the horizon
The absence of reliable CSC biomarkers continuously stimulates BC research, in order to identify BCSC in ex vivo models, and thus improve their identification and enrichment in the tumor microenvironment , and elucidate the biological basis of BC heterogeneity and drug resistance .
In general, CD44high/CD24low cell surface markers were the most efficient panel for selecting normal epithelial progenitors. Further fractionation of CD44high/CD24low cells may select for luminal progenitors within Ep-CAMhigh/CD49f+ cell types, and for basal progenitors within Ep-CAM- or low/CD49f+.
Primary BC tissues (mainly luminal Ep-CAMhigh) were found to contain CD44high/CD24low cells in both CD49f- and CD49f+ cancer cell fractions. Ghebeh et al. showed for the first time that the CD44high/CD24low subpopulation within CD49fhigh cell types had the highest efficiency compared with other well-known subpopulations (based on MUC-1-, ALDH+, and CD10+ expression).
From a cancer biology point of view, Ghebeh et al. have performed an interesting and comprehensive study comparing various subpopulations of cells with stem cell-like properties, supporting the notion that BCSC were predominantly CD49f+, and proposing the use of CD44high/CD24low in combination with Ep-CAM/CD49f as valuable biomarkers to identify BC cells with enhanced mammosphere-forming and colony-forming ability.
What do the CD44+/CD24-/low and Ep-CAM+/CD49f+biomarker combinations really tell us about the biology of breast cancer and the heterogeneity of cancer stem cells?
The phenotype of the normal human mammary gland stem/progenitor cells has been previously described in various reports as ALDHhigh, CD10+, CD44high/CD24low or Ep-CAM+/MUC1- and CD49f+.
Ghebeh et al. found that human mammary epithelial cells with a CD44high/CD24low phenotype had the highest progenitor ability, providing a convincing demonstration that, in both normal and malignant breasts, there are multiple CD44high/CD24low subpopulations. Within the basal Ep-CAM-/low/CD49f+ cells, the subpopulation of CD44high/CD24low has the highest progenitor ability, whereas CD10- cells have the lowest progenitor ability (that is, the lowest number of differentiated myoepithelial cells).
It is known that luminal mammary epithelial cells have a estrogen receptor-positive (ER+) cell population, whereas proliferating normal luminal cells are known to be ER-. Interestingly, Ghebeh et al. showed a correlation between the CD44high/CD24low phenotype and ER- profile in normal mammary epithelial cells within Ep-CAMhigh/CD49f+, in full agreement with the progenitor ability of these cells.
As depicted in Figure 1, there is a clear drift in patients with BC towards population C (Ep-CAMhigh/CD49f-) which almost doubled, whereas population A (Ep-CAM-/low/CD49f+) dramatically decreased in BC compared with healthy tissue.
For the first time, it has been shown that the majority of BCSC with CD44high/CD24low phenotype exist mainly in the Ep-CAMhigh/CD49f+ fraction of cancer cells, revealing a significant difference in CD44high/CD24low expression (in Ep-CAMhigh BC cells) between ER and basal subtypes of BC in CD49f+ cancer cells only . In other words, putting together the pieces of the puzzle, these data imply that CD49f (α-6 integrin molecule), if used in combination with CD44high/CD24low markers, may be able to link the stem/progenitor cell profile with the heterogeneity of BC subtypes. Thus, BCSCs can best be enriched by selecting for tumor cells with the CD44high/CD24low/ALDHhigh phenotypes within Ep-CAMhigh/CD49f+ BC cells.
Conclusions and future perspectives
Improving technological methods, such as single-cell analysis  for earlier detection and diagnosis of human BC, in conjunction with the discovery and validation of powerful combinations of BCSC biomarkers, may represent key tools to obtain a significant reduction in morbidity and mortality in BC.
Analysis of the BC microenvironment [6, 7, 23] and the novel identification of pure/specific epithelial stem/progenitor cells , will allow detection of alterations within biochemical, morphological, and molecular pathways promoting cancer initiation, progression, invasion, and metastasis, taking into account the different stem/non-stem cell compositions and interactions in the human breast microenvironment [11, 17, 18].
Therefore, although confirmatory studies are needed, it is time to move on to the new paradigm highlighted by Ghebeh et al., namely, that the majority of BC cells have a luminal Ep-CAMhigh phenotype with a very small percentage of cancer cells of the Ep-CAM-/low/CD49f+ phenotype.
Further research is required, which should focus on single-cell omic approaches, with particular attention on basal Ep-CAMlow primary cancer cells, as these may correspond to the mammary stem cell-enriched population in the normal breast gland.
Finally, the recently published study in BMC Cancer on CD44high/CD24low/CD49f+ biomarkers represents a shining example of how the combination of more biomolecules (singularly not perfectly accurate) may significantly improve and strengthen the measurement of BCSCs with significantly higher stem/progenitor ability. These experiments suggest that these biomarkers will be a useful BC biomarker panel and the best phenotype to identify human BCSCs and to better understand BC biology.
Future developments in onco-single-cell-omics  will potentially revolutionize cancer biology and clinical practice, providing better understanding of BC heterogeneity, how BCSCs evolve, and which BC cells to target in order to avoid drug resistance .
FM holds a professional position as Aggregate Professor of Cell Biology at the University ‘Carlo Bo’ of Urbino, care of the Dept of Biomolecular Sciences. He has held the position of the Chief Investigator of Grant Awards on Intraductal Approach to Breast Cancer Research, funded by DSLRF (Santa Monica, CA, USA) since 2005, and has been President of the Association of Fight Against Cancer of Urbino (AULCT-ONLUS), Italy since 2009.
Breast cancer stem cell
Cancer stem cell
The Dr Susan Love Research Foundation (Santa Monica, CA, USA) is kindly acknowledged for the support to Prof F Mannello (Research Grant Award 2011). I thank Dr. Daniela Ligi for her skilful assistance in figure elaboration.
- Hsiao YH, Chou MC, Fowler C, Mason JT, Man YG: Breast cancer heterogeneity: mechanisms, proofs, and implications. J Cancer. 2010, 1: 6-13.PubMedPubMed CentralView Article
- Dawson SJ, Rueda OM, Aparicio S, Caldas C: A new genome-driven integrated classification of breast cancer and its implications. EMBO J. 2013, 32: 617-628. 10.1038/emboj.2013.19.PubMedPubMed CentralView Article
- Almendro V, Marusyk A, Polyak K: Cellular heterogeneity and molecular evolution in cancer. Annu Rev Pathol. 2013, 8: 277-302. 10.1146/annurev-pathol-020712-163923.PubMedView Article
- Siegel R, Naishadham D, Jemal A: Cancer statistics, 2013. CA Cancer J Clin. 2013, 63: 11-30. 10.3322/caac.21166.PubMedView Article
- Polyak K: Heterogeneity in breast cancer. J Clin Invest. 2011, 121: 3786-3788. 10.1172/JCI60534.PubMedPubMed CentralView Article
- Place AE, Jin HS, Polyak K: The microenvironment in breast cancer progression: biology and implications for treatment. Breast Cancer Res. 2011, 13: 227-10.1186/bcr2912.PubMedPubMed CentralView Article
- Mannello F, Medda V, Tonti GA: Protein profile analysis of the breast microenvironment to differentiate healthy women from breast cancer patients. Expert Rev Proteomics. 2009, 6: 43-60. 10.1586/147894126.96.36.199.PubMedView Article
- Higgins MJ, Baselga J: Targeted therapies for breast cancer. J Clin Invest. 2011, 121: 3797-3803. 10.1172/JCI57152.PubMedPubMed CentralView Article
- Gangopadhyay S, Nandy A, Hor P, Mukhopadhyay A: Breast cancer stem cells: a novel therapeutic target. Clin Breast Cancer. 2013, 13: 7-15. 10.1016/j.clbc.2012.09.017.PubMedView Article
- Ablett MP, Singh JK, Clarke RB: Stem cells in breast tumours: are they ready for the clinic?. Eur J Cancer. 2012, 48: 2104-2116. 10.1016/j.ejca.2012.03.019.PubMedView Article
- Valent P, Bonnet D, Wohrer S, Andreeff M, Copland M, Chomienne C, Eaves C: Heterogeneity of neoplastic stem cells: theoretical, functional, and clinical implications. Cancer Res. 2013, 73: 1037-1045. 10.1158/0008-5472.CAN-12-3678.PubMedView Article
- Polyak K, Vogt PK: Progress in breast cancer research. Proc Natl Acad Sci USA. 2012, 109: 2715-2717. 10.1073/pnas.1201091109.PubMedPubMed CentralView Article
- Virchow R: Die cellular pathologie in ihrer begründung auf physiologische und pathologische gewebelehre. 1858, Berlin: Von August Hirschwald
- Nowell PC: The clonal evolution of tumor cell populations. Science. 1976, 194: 23-28. 10.1126/science.959840.PubMedView Article
- Li Y, Laterra J: Cancer stem cells: distinct entities or dynamically regulated phenotypes?. Cancer Res. 2012, 72: 576-580. 10.1158/0008-5472.CAN-11-3070.PubMedPubMed CentralView Article
- Vermeulen L, de Sousa EM, Richel DJ, Medema JP: The developing cancer stem-cell model: clinical challenges and opportunities. Lancet Oncol. 2012, 13: e83-e89. 10.1016/S1470-2045(11)70257-1.PubMedView Article
- Tang DG: Understanding cancer stem cell heterogeneity and plasticity. Cell Res. 2012, 22: 457-472. 10.1038/cr.2012.13.PubMedPubMed CentralView Article
- Medema JP: Cancer stem cells: the challenges ahead. Nat Cell Biol. 2013, 15: 338-344. 10.1038/ncb2717.PubMedView Article
- Al-Hajj M, Wicha MS, Ito-Hernandez A, Morrison SJ, Clarke MF: Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A. 2003, 100: 3983-3988. 10.1073/pnas.0530291100.PubMedPubMed CentralView Article
- Ginestier C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J, Brown M, Jacquemier J, Viens P, Kleer CG, Liu S, et al: ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell. 2007, 1: 555-567. 10.1016/j.stem.2007.08.014.PubMedPubMed CentralView Article
- Ghebeh H, et al: Profiling of normal and malignant breast tissues show CD44high/CD24low phenotype as a predominant stem/progenitor marker when used in combination with Ep-CAM/CD49f markers. BMC Cancer. 2013, 13: 289-10.1186/1471-2407-13-289.PubMedPubMed CentralView Article
- Valent P, Bonnet D, De MR, Lapidot T, Copland M, Melo JV, Chomienne C, Ishikawa F, Schuringa JJ, Stassi G, et al: Cancer stem cell definitions and terminology: the devil is in the details. Nat Rev Cancer. 2012, 12: 767-775. 10.1038/nrc3368.PubMedView Article
- Mannello F, Ligi D, Magnani M: Deciphering the single-cell omic: innovative application for translational medicine. Expert Rev Proteomics. 2012, 9: 635-648. 10.1586/epr.12.61.PubMedView Article
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1741-7015/11/169/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.